| Joseph M Mcginley, DO | |
|
856 Interchange Rd, Lehighton, PA 18235-9286 | |
| (610) 377-9020 | |
| Not Available |
| Full Name | Joseph M Mcginley |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 22 Years |
| Location | 856 Interchange Rd, Lehighton, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861518706 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | OS012837 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Luke's Miners Memorial Hospital | Coaldale, PA | Hospital |
| St Luke's Hospital Bethlehem | Bethlehem, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| St Luke's Physician Group Inc | 6709798333 | 1739 |
News Archive
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.
If Julie Johnson had her way, doctors would check a patient's genes before writing a prescription. Everyone responds differently to medicines—one that works for you might not work for me, or it could even be harmful. These individual responses depend to an extent on our genetic make-up.
These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.
According to a study published online in the Journal of Personalized Medicine, fitness activity trackers measure heart rates precisely but not the number of calories burned.
› Verified 3 days ago
| Entity Name | The Carbon-schuylkill Community Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194891010 PECOS PAC ID: 4486562030 Enrollment ID: O20031117000015 |
News Archive
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.
If Julie Johnson had her way, doctors would check a patient's genes before writing a prescription. Everyone responds differently to medicines—one that works for you might not work for me, or it could even be harmful. These individual responses depend to an extent on our genetic make-up.
These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.
According to a study published online in the Journal of Personalized Medicine, fitness activity trackers measure heart rates precisely but not the number of calories burned.
› Verified 3 days ago
| Entity Name | St Lukes Physician Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700984622 PECOS PAC ID: 6709798333 Enrollment ID: O20040226000062 |
News Archive
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.
If Julie Johnson had her way, doctors would check a patient's genes before writing a prescription. Everyone responds differently to medicines—one that works for you might not work for me, or it could even be harmful. These individual responses depend to an extent on our genetic make-up.
These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.
According to a study published online in the Journal of Personalized Medicine, fitness activity trackers measure heart rates precisely but not the number of calories burned.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joseph M Mcginley, DO 856 Interchange Rd, Lehighton, PA 18235-9286 Ph: (610) 377-9020 | Joseph M Mcginley, DO 856 Interchange Rd, Lehighton, PA 18235-9286 Ph: (610) 377-9020 |
News Archive
Pharmasset, Inc. has received fast track designation from the U.S. Food and Drug Administration for PSI-7977 for the treatment of chronic hepatitis C virus infection. PSI-7977 is an oral uridine nucleotide analog polymerase inhibitor of HCV. Pharmasset recently completed dosing in a 28 day Phase 2a trial to evaluate PSI-7977 in combination with Pegasys (pegylated interferon) plus Copegus (ribavirin) in treatment-naive patients chronically infected with HCV genotype 1.
Lexicon Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, $95,000,000 of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. Lexicon also intends to grant the underwriters a 30-day option to purchase up to an additional $14,250,000 of common stock to cover over-allotments, if any.
If Julie Johnson had her way, doctors would check a patient's genes before writing a prescription. Everyone responds differently to medicines—one that works for you might not work for me, or it could even be harmful. These individual responses depend to an extent on our genetic make-up.
These are exciting times for regenerative medicine. Unlike conventional medicines, the regenerative approach can potentially work to restore the lost functionality of tissues or organs—the major reason for intensive focus on research and development in the field.
According to a study published online in the Journal of Personalized Medicine, fitness activity trackers measure heart rates precisely but not the number of calories burned.
› Verified 3 days ago
Dimitry Belogorodsky, DO Family Medicine Medicare: Medicare Enrolled Practice Location: 2226 Blakeslee Boulevard Dr E, Lehighton, PA 18235 Phone: 610-297-3003 | |
Dr. Peter J Baddick Iii, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 2175 Blakeslee Boulevard Dr W, Lehighton, PA 18235 Phone: 570-386-4171 Fax: 570-386-2429 | |
Daniel George Walker, DO Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2175 Blakeslee Boulevard Dr W, Lehighton, PA 18235 Phone: 570-386-4171 | |
David Thomas Ogurek, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 363 N 1st St, Lehighton, PA 18235 Phone: 484-464-9510 | |
Kenneth R Sharp, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 363 N 1st St, Lehighton, PA 18235 Phone: 484-464-9510 Fax: 484-464-9515 | |
Ismat Ahmad, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 St Lukes Dr, Lehighton, PA 18235 Phone: 484-526-4500 | |
Dennis James Kondash, D.O. Family Medicine Medicare: Medicare Enrolled Practice Location: 211 N 12th St, Lehighton, PA 18235 Phone: 610-377-7174 Fax: 610-377-4785 |